Our goal was to develop a non-surgical model of atherosclerosis regression in mice with incipient metabolic syndrome and insulin-deficient diabetes mellitus, using these as examples of the flexibility afforded by use of HDAd-LDLR treatment to study regression under differing metabolic conditions. Here, LDLR is linked to metabolic syndrome.